ARID1A and breast neoplasm: Moreover, using GSE32646 data set,25 among patients receiving paclitaxel‐based NAC, ARID1A mRNA levels in TNBC, but not breast tumour of ER(+) and HER2(+), derived from patients with nCR were significantly (P < .05) decreased compared to those of patients with pCR (Figure 5F).